(S)-UFR2709 hydrochloride,98.08%

产品编号:Bellancom-137231B| 分子式:C13H18ClNO2| 分子量:255.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-137231B
1000.00 杭州 北京(现货)
Bellancom-137231B
1500.00 杭州 北京(现货)
Bellancom-137231B
3000.00 杭州 北京(现货)
Bellancom-137231B
4500.00 杭州 北京(现货)
Bellancom-137231B
7000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

(S)-UFR2709 hydrochloride

产品介绍 (S)-UFR2709 (hydrochloride) 是一种竞争性的 nAChR 拮抗剂,并显示出较强的亲和力,对 α4β2 nAChR 的亲和力比对 α7 nAChR 的高。(S)-UFR2709 (hydrochloride) 在偏好酒精的老鼠中减少焦虑,并且可以减少其酒精摄入和对酒精偏好。(S)-UFR2709 (hydrochloride) 是抗焦虑试剂,可用于研究尼古丁成瘾。
生物活性

(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction.

体外研究

Brain nicotinic acetylcholine receptors (nAChRs) is a heterogeneous family of pentameric acetylcholine-gated cation channels, which is a molecular target for the treatment of alcohol abuse and dependence.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

(S)-UFR2709 (hydrochloride) (50-100 μg/ml; 3 min and then maintained for another 5 min in a holding tank before testing the swimming behaviour in the test tank for a period of 5 min) produces a decrease in the bottom dwelling for NTT test, and UFR2709 induces a significant and dose-dependent decrease in bottom dwelling time to 52.9 and 87.0 s, respectively at 50 and 100 μg/ml.
(S)-UFR2709 (hydrochloride) (50-100 μg/ml) decreases nicotine-evoked mRNA expression of α4 nACh receptor subunit, but UFR2709 has less effect on α4 nACh receptor subunit in the brain of adult zebrafish.
(S)-UFR2709 (hydrochloride) (intraperitoneal injection; 1-10 mg/kg; daily; 17 days) reduces ethanol consumption and ethanol preference and increased water consumption in a dose-dependent manner. The most effective dose of UFR2709 is 2.5 mg/kg, it induces a 56% reduction in alcohol consumption. (S)-UFR2709 (hydrochloride) does not affect the weight or locomotor activity of the rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: High-alcohol-drinking UChB rats
Dosage: 10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg
Administration: Intraperitoneal injection; 1-10 mg/kg; daily; 17 days
Result: Did not affect the weight or locomotor activity and reduced ethanol consumption and preference.
体内研究

(S)-UFR2709 (hydrochloride) (50-100 μg/ml; 3 min and then maintained for another 5 min in a holding tank before testing the swimming behaviour in the test tank for a period of 5 min) produces a decrease in the bottom dwelling for NTT test, and UFR2709 induces a significant and dose-dependent decrease in bottom dwelling time to 52.9 and 87.0 s, respectively at 50 and 100 μg/ml.
(S)-UFR2709 (hydrochloride) (50-100 μg/ml) decreases nicotine-evoked mRNA expression of α4 nACh receptor subunit, but UFR2709 has less effect on α4 nACh receptor subunit in the brain of adult zebrafish.
(S)-UFR2709 (hydrochloride) (intraperitoneal injection; 1-10 mg/kg; daily; 17 days) reduces ethanol consumption and ethanol preference and increased water consumption in a dose-dependent manner. The most effective dose of UFR2709 is 2.5 mg/kg, it induces a 56% reduction in alcohol consumption. (S)-UFR2709 (hydrochloride) does not affect the weight or locomotor activity of the rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: High-alcohol-drinking UChB rats
Dosage: 10 mg/kg, 5 mg/kg, 2.5 mg/kg, or 1 mg/kg
Administration: Intraperitoneal injection; 1-10 mg/kg; daily; 17 days
Result: Did not affect the weight or locomotor activity and reduced ethanol consumption and preference.
性状Solid
溶解性数据
In Vitro: 

H2O : 100 mg/mL (391.02 mM; Need ultrasonic)

DMSO : 50 mg/mL (195.51 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.9102 mL 19.5511 mL 39.1022 mL
5 mM 0.7820 mL 3.9102 mL 7.8204 mL
10 mM 0.3910 mL 1.9551 mL 3.9102 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 50 mg/mL (195.51 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (9.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 4.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.78 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服